Marlinz Pharma is proud to announce the January 2017 launch of its Tolcylen™ Antifungal, Cosmetic and Nail Renewal product. Working with a team of experienced pharmacological scientists, the Tolcylen™ Antifungal/Nail Renewal Solution formulation was developed, tested and stabilized. Initially developed to be marketed as a prescription topical onychomycosis drug, Tolcylen™ was eventually perfected and introduced to the market as an OTC physician dispensed product. The highly specialized solution resulted in the filing of multiple patent applications covering the processes and formulations. The solution is delivered via a patented soft tube/applicator brush tip flow restrictor. The brush tip easily reaches the hyponychial and nail fold areas while the leak proof cap prevents waste and evaporation. Tolcylen™ Solution is the only product of any kind capable of rapidly improving the appearance of compromised nails with cosmetic agents, while also introducing an antifungal agent to the infected sites via a low molecular weight and low surface tension vehicle. Scientific and clinical data are available for licensed practitioners.
Marlinz Pharma announces the milestone of 50,000 units of Tolcylen™ products dispensed as of August 21, 2017. Since our full scale launch only 6 months ago over 500 accounts have made Tolcylen™ their standard office based treatment for onychomycosis and other nail pathologies. Several comparative studies and clinical white papers are underway and early results are outstanding. Marlinz Pharma has also completed the filing of our 5th patent application to cover the existing and new product combinations, formulations, surfactants and related proprietary processes making up the cornerstone of our one of a kind product portfolio.